GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (XPAR:ALCOX) » Definitions » Effective Interest Rate on Debt %

Nicox (XPAR:ALCOX) Effective Interest Rate on Debt % : 6.50% (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Nicox Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Nicox's annualized positive value of Interest Expense for the quarter that ended in Dec. 2023 was €1.50 Mil. Nicox's average total debt for the quarter that ended in Dec. 2023 was €23.15 Mil. Therefore, Nicox's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 was 6.50%.


Nicox Effective Interest Rate on Debt % Historical Data

The historical data trend for Nicox's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nicox Effective Interest Rate on Debt % Chart

Nicox Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.59 13.90 9.97 6.84 6.37

Nicox Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.08 8.31 6.19 7.45 6.50

Competitive Comparison of Nicox's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Nicox's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nicox's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nicox's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Nicox's Effective Interest Rate on Debt % falls into.



Nicox Effective Interest Rate on Debt % Calculation

Nicox's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -1.633/( (26.125+25.153)/ 2 )
=-1  *  -1.633/25.639
=6.37 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=25.297 + 0.828
=26.125

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=25.153 + 0
=25.153

Nicox's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Jun. 2023 )+Total Debt  (Q: Dec. 2023 ))/ count )
=-1  *  -1.504/( (21.154+25.153)/ 2 )
=-1  *  -1.504/23.1535
=6.50 %

where

Total Debt  (Q: Jun. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=18.381 + 2.773
=21.154

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=25.153 + 0
=25.153

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is two times the semi-annual (Dec. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Nicox  (XPAR:ALCOX) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Nicox Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Nicox's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nicox (XPAR:ALCOX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nicox SA (XPAR:ALCOX) » Definitions » Effective Interest Rate on Debt %
Traded in Other Exchanges
Address
2405 route des Dolines, Drakkar 2 -Batiment D, Valbonne, Sophia Antipolis, FRA, 06560
Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. Nicox's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.

Nicox (XPAR:ALCOX) Headlines

No Headlines